Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/188911
Title: Prevalence of HPV-DNA and E6 mRNA in lung cancer of HIV-infected patients
Author: Sirera, Guillem
Videla, Sebastián
Saludes, Verónica
Castellà, Eva
Sanz, Carolina
Ariza, Aurelio
Clotet, Bonaventura, 1953-
Martró, Elisa
Keywords: Càncer de pulmó
Persones seropositives
Infeccions per VIH
Lung cancer
HIV-positive persons
HIV infections
Issue Date: 1-Aug-2022
Publisher: Springer Science and Business Media LLC
Abstract: HIV-infected individuals could be at a greater risk for developing lung cancer than the general population due to the higher prevalence in the former of human papillomavirus (HPV) in the oral cavity and higher smoking rates. Our aim was to assess HPV prevalence and E6 viral oncogene transcription in lung cancer samples from HIV-infected individuals. This was a single-center, retrospective study of a cohort of HIV-1-infected patients diagnosed with and treated for lung cancer. Pathological lung samples archived as smears or formalin-fixed paraffin-embedded blocks were subjected to HPV genotyping, detection of human p16 protein and assessment for HPV E6 mRNA expression. Lung cancer samples from 41 patients were studied, including squamous cell carcinoma (32%), adenocarcinoma (34%), non-small cell cancer (27%), and small cell cancer (7%). HPV DNA was detected in 23 out of 41 (56%, 95% CI 41-70%) of samples and high-risk (HR)-HPV types were detected in 16 out of 41 (39%, 95% CI 26-54%), HPV-16 being the most prevalent [13/16 (81.3%, 95% CI 57.0-93%]. In samples with sufficient material left: expression of p16 was detected in 3 out of 10 (30%) of HR-HPV DNA-positive tumors and in 3 out of 7 (43%) of the negative ones; and E6 mRNA was detected in 2 out of 10 (20%) of HPV-16-positive samples (squamous lung cancers). These two patients had a background of a previous HPV-related neoplasia and smoking. HR-HPV DNA detection was prevalent in lung cancers in HIV-infected patients. However, viral oncogene expression was limited to patients with previous HPV-related cancers.
Note: Reproducció del document publicat a: https://doi.org/10.1038/s41598-022-17237-5
It is part of: Scientific Reports, 2022, vol. 12, num. 1, p. 13196
URI: http://hdl.handle.net/2445/188911
Related resource: https://doi.org/10.1038/s41598-022-17237-5
ISSN: 2045-2322
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
s41598-022-17237-5.pdf1.16 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons